Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
Timothy Arthur Chandos SnowNaveed SaleemGareth AmblerEleni NastouliMervyn SingerNishkantha ArulkumaranPublished in: Intensive care medicine (2021)
For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required. Its benefits may also lie in reducing the need for mechanical ventilation.
Keyphrases
- mechanical ventilation
- sars cov
- rheumatoid arthritis
- acute respiratory distress syndrome
- juvenile idiopathic arthritis
- intensive care unit
- coronavirus disease
- rheumatoid arthritis patients
- respiratory failure
- study protocol
- cardiovascular events
- electronic health record
- phase iii
- extracorporeal membrane oxygenation
- respiratory syndrome coronavirus
- big data
- cardiovascular disease
- type diabetes
- deep learning
- artificial intelligence
- open label